Physician profile
David E Yomtoob
NPI 1841487030
$14,315.56
in general payments reported to CMS, 2019-2025
30 companies · $706 in 2025
The $706 reported for 2025 was more than what a typical Ophthalmology provider received nationally (typical 2025 total: $384).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,335 · 2020: $2,171 · 2021: $2,371 · 2022: $742 · 2023: $4,586 · 2024: $2,405 · 2025: $706.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $4,335 · Food and Beverage: $3,336 · Honoraria: $25.59.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $4,335.00 |
| Food and Beverage | $3,335.65 |
| Honoraria | $25.59 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaukos Corporation | $4,616.24 | 2019-2025 | Idose, Photrexa Cross-Linking Kit, Idosetr |
| Abbvie INC. | $2,303.55 | 2022-2025 | Lumigan, Alphagan P, Combigan |
| Johnson & Johnson Surgical Vision, INC. | $2,019.93 | 2019-2025 | Tecnis Simplicity, Veritas Vision System, Tecnis Iol |
| Sight Sciences, INC. | $670.75 | 2019-2025 | Omni Surgical System, Sion Surgical Instrument |
| Aerie Pharmaceuticals, INC. | $569.13 | 2019-2021 | |
| Alcon Vision LLC | $543.62 | 2019-2025 | Rocklatan, Tryptyr |
| New World Medical,INC. | $458.88 | 2019-2024 | Streamline, Kahook Dual Blade, Ahmed Glaucoma Valve |
| Allergan, INC. | $384.17 | 2019-2022 | |
| Sun Pharmaceutical Industries INC. | $336.56 | 2019-2025 | |
| Bausch & Lomb Americas INC. | $256.68 | 2022-2025 | Miebo, Vyzulta, Xiidra |
| Nova Eye, INC. | $230.04 | 2024-2025 | |
| Oyster Point Pharma, INC. | $214.19 | 2022-2024 | Tyrvaya, Ryzumvi |
| Dompe US, INC. | $194.88 | 2021-2025 | Oxervate |
| Thea Pharma INC. | $154.83 | 2023-2025 | Iyuzeh |
| Shire North American Group INC | $153.42 | 2019 |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Rxsight INC | $151.55 | 2022-2024 | Rxsight Light Delivery Device (Ldd), Rxsight Injector Cartridge, Rxsight Injector Handpiece |
| Carl Zeiss Meditec USA, INC. | $151.35 | 2023 | Forum |
| Tarsus Pharmaceuticals, INC. | $145.74 | 2024-2025 | Xdemvy |
| Novartis Pharmaceuticals Corporation | $145.67 | 2019-2023 | |
| Eyevance Pharmaceuticals LLC | $117.61 | 2019-2022 | |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $90.71 | 2019-2021 | |
| Horizon Therapeutics Plc | $90.00 | 2023 | Tepezza |
| Amgen INC. | $81.14 | 2024-2025 | Tepezza |
| Carl Zeiss Meditec, INC. | $70.14 | 2024 | |
| Mallinckrodt Hospital Products INC. | $48.60 | 2021 | |
| Akorn, INC. | $46.81 | 2019 | |
| Akorn Operating Company LLC | $39.25 | 2021 | |
| Ocular Therapeutix, INC. | $14.92 | 2021 | |
| Oasis Medical, INC. | $14.37 | 2019 | |
| Travere Therapeutics, INC. | $0.83 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw David Yomtoob listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.